Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Sclerosis and Related Disorders Channel:
MOGAD

Welcome to The MOGAD Channel

VJNeurology brings you the latest updates in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) directly from world-leading experts. The MOGAD Channel brings you video interviews from international conferences.

Discover key developments in this space, including updates in disease biology, novel treatment strategies, and ongoing clinical trials.

Relationship between patient-reported outcomes, sociodemographic variables, and EDSS scores in MOGAD 1:36
Relationship between patient-reported outcomes, sociodemographic variables, and EDSS scores in MOGAD
Dalia Rotstein • 19 Feb 2026
Clinical presentation of MS, NMOSD, and MOGAD: differentiating between the three conditions 3:39
Clinical presentation of MS, NMOSD, and MOGAD: differentiating between the three conditions
Marcello Moccia • 2 Oct 2025
Including central vein sign in McDonald criteria to distinguish MS from similar diseases 1:34
Including central vein sign in McDonald criteria to distinguish MS from similar diseases
Celia Oreja-Guevara • 23 Jun 2025
Is there a prodromal phase in MOGAD or NMOSD? 4:54
Is there a prodromal phase in MOGAD or NMOSD?
Dalia Rotstein • 12 Mar 2024
Standards for antibody testing in MOGAD 2:03
Standards for antibody testing in MOGAD
Jodie Burton • 20 Oct 2023
Emerging therapies in MOGAD 4:49
Emerging therapies in MOGAD
Jodie Burton • 20 Oct 2023
Advancements in MOGAD diagnosis: key features of the new guidelines 2:28
Advancements in MOGAD diagnosis: key features of the new guidelines
Jodie Burton • 20 Oct 2023
Predicting relapses in MOGAD 1:17
Predicting relapses in MOGAD
Torge Rempe • 20 Oct 2023
Assessing predictors of relapse in MOGAD patients 5:32
Assessing predictors of relapse in MOGAD patients
Torge Rempe • 20 Oct 2023
Elevated intracranial pressure in MOGAD patients with bilateral optic neuritis 1:36
Elevated intracranial pressure in MOGAD patients with bilateral optic neuritis
Torge Rempe • 20 Oct 2023
Analysis of the diagnostic utility of cerebrospinal fluid MOG-IgG 5:42
Analysis of the diagnostic utility of cerebrospinal fluid MOG-IgG
Vyanka Redenbaugh • 20 Oct 2023
Current MOGAD criteria and the role of MRI in diagnosis 1:04
Current MOGAD criteria and the role of MRI in diagnosis
Vyanka Redenbaugh • 20 Oct 2023
Emerging trials on treatments for MOGAD 0:44
Emerging trials on treatments for MOGAD
Vyanka Redenbaugh • 20 Oct 2023
Concurrent malignant tumor near the onset of MOGAD 3:08
Concurrent malignant tumor near the onset of MOGAD
Young Nam Kwon • 5 Oct 2023
Predictors of conversion from positive to negative MOG antibody status 1:44
Predictors of conversion from positive to negative MOG antibody status
Michael Levy • 26 Apr 2023
IgA: a new biomarker of demyelinating disease 5:04
IgA: a new biomarker of demyelinating disease
Anne-Katrin Pröbstel • 26 Apr 2023
The content of VJNeurology is intended for healthcare professionals